News

EULAR Straddles the Data-Opinion Gap on Hip OA

Publish date: July 1, 2005
PDF Download

 

We [need to] answer the question of when exactly to recommend and perform THR.

Pages

Recommended Reading

TNF Blockers Linked to Severe Skin Reactions : Overall, 25% of patients taking the biologics had a dermatologic event compared with 13% of controls.
MDedge Rheumatology
Data Watch
MDedge Rheumatology
Belimumab, Rituximab Are Next in the Biologic Pipeline for RA
MDedge Rheumatology
TNF Blockers Up Lymphoma Risk : Experts say the study was too small to reach a 'robust conclusion' about such drug-related risks.
MDedge Rheumatology
Out of Africa: Retrovirus Connected to Autoimmune Diseases
MDedge Rheumatology
Review Shows Anti-TNF Treatment Is Best in AS
MDedge Rheumatology
Etanercept Shows Sustained Benefit for Psoriatic Arthritis
MDedge Rheumatology
Treatment With Low-Dose Biologics For Rheumatic Disease Cuts Costs
MDedge Rheumatology
Ankylosing Spondylitis: Risk for Renal Stones
MDedge Rheumatology
Serious Infection Rates Similar Among Biologics
MDedge Rheumatology